Earnings calls

Gland Pharma concall ledger

Every earnings call for GLAND — management tone, guidance, KPIs and promise tracking, quarter by quarter.

GLAND · 5 transcripts · Healthcare · latest Q3 FY26

Q3 FY26Published 28 Jan 2026Call held 28 Jan 2026

GLAND Q3 FY26 Earnings Call Transcript & Analysis

Revenue16,954 million+22% YoYAdjusted EBITDA4,490 million+25% YoYEBITDA Margin26%Adjusted PAT2,797 million

Revenue 16954 million (+22% YoY); Adjusted EBITDA 4490 million (+25% YoY); EBITDA Margin 26%. Consolidated revenue reached ₹16,954 million, representing a 22% YoY growth.

Read full transcript & analysis

Q2 FY26Published 03 Nov 2025Call held 03 Nov 2025

GLAND Q2 FY26 Earnings Call Transcript & Analysis

Revenue14,869 million+6% YoYEBITDA Margin21%PAT1,837 million+12% YoY

Revenue 14869 million (+6% YoY); EBITDA Margin 21%; PAT 1837 million (+12% YoY). Consolidated Revenue reached ₹14,869 million, representing a 6% YoY growth.

Read full transcript & analysis

Q1 FY26Published 05 Aug 2025Call held 05 Aug 2025

GLAND Q1 FY26 Earnings Call Transcript & Analysis

Revenue15,056 million+7% YoYEBITDA3,678 million+39% YoYEBITDA Margin24%PAT2,155 million+50% YoY

Revenue 15056 million (+7% YoY); EBITDA 3678 million (+39% YoY); EBITDA Margin 24%. Consolidated Revenue reached ₹15,056 million, representing a 7% YoY growth.

Read full transcript & analysis

Q4 FY25Published 20 May 2025Call held 20 May 2025

GLAND Q4 FY25 Earnings Call Transcript & Analysis

Revenue₹1,424.9 crEBITDA Margin24%PAT₹186.5 cr+3% YoY

Revenue ₹1,425 cr; EBITDA Margin 24.0%; PAT ₹186 cr (+3% YoY). Consolidated Revenue for Q4 FY25 stood at ₹1,424.9 crores, showing sequential improvement over Q3.

Read full transcript & analysis

Q3 FY25Published 03 Feb 2025Call held 03 Feb 2025

GLAND Q3 FY25 Earnings Call Transcript & Analysis

Revenue13,841 million INREBITDA Margin26%PAT2,047 million INR+7% YoY

Revenue 13841 million INR; EBITDA Margin 26%; PAT 2047 million INR (+7% YoY). Consolidated Revenue stood at ₹1,384.1 crore (INR 13,841 million), with a consolidated EBITDA margin of 26%, up 300 bps YoY.

Read full transcript & analysis